Inactivation and Clearance of Viruses During the Manufacture of High Purity Factor IX
β Scribed by Anna Johnston; Andrew Macgregor; Steven Borovec; Meghan Hattarki; Keith Stuckly; David Anderson; Neil H. Goss; Adrian Oates; Eric Uren
- Book ID
- 112237774
- Publisher
- Elsevier Science
- Year
- 2000
- Tongue
- English
- Weight
- 121 KB
- Volume
- 28
- Category
- Article
- ISSN
- 1045-1056
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Recent reports have suggested an increased risk of type A viral hepatitis in hemophilic patients treated with high purity factor VIII concentrates prepared using ion exchange chromatography coupled with solvent/detergent treatment for inβactivation of viruses. To determine the capacity
The efficacy of two heating cycles (90 sec at 103 O C and 10 hr at 65 "C) used during manufacture of a plasma-derived hepatitis-B vaccine was validated for the inactivation of 12 virus families. A period of 15 min warming up to 65 O C had already completely inactivated representatives of nine virus